Most Read Articles
Roshini Claire Anthony, 13 Aug 2018

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

19 Jul 2018
Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to increase the risk of major bleeding, stroke or systemic embolism, and hospitalization among patients with atrial fibrillation (AF), suggest the results of the RE-LY* trial. Moreover, there is no difference in the safety and efficacy of dabigatran etexilate (DE) 150 and 110 mg twice daily relative to warfarin.
Rachel Soon, 01 Mar 2018

Over half of consumers who use herbal supplements still do not inform physicians of their practices in consultation, according to a local study.

Tumour necrosis factor inhibitors for RA do not increase risk of cancer relapse

12 Oct 2018

Treatment with tumour necrosis factor inhibitor (TNFi) does not carry a heightened risk of cancer recurrence in patients with rheumatoid arthritis (RA) and a history of cancer, as shown in a recent study.

Researchers followed 467 adult RA patients who initiated TNFi treatment at a mean of 7.9 years after being diagnosed with cancer, evaluating cancer recurrence in comparison with 2,164 matched RA controls and a history of the same cancer but who had never received biologics.

Cancer recurrences occurred in 42 TNFi-treated patients during a mean follow-up of 5.3 years and in 155 biologics-naïve controls during a mean follow-up of 4.3 years (9.0 percent vs 7.2 percent). Adjusted Cox proportional hazards analysis revealed that TNFi treatment was not associated with any increase in the risk of recurrence (hazard ratio [HR], 1.06; 95 percent CI, 0.73–1.54).

However, researchers noted that several estimates from subgroup analyses had CIs with upper limits around 2 or above, suggesting that a clinically relevant risk for cancer recurrence could not be ruled out.

The study was limited by the outcome algorithm being partly nonvalidated. Also, it is possible that clinicians gave TNFi drugs only to the patients they thought had a better cancer prognosis–in other words, a low risk of relapse.

The findings should therefore be interpreted with treatment channelling in mind. Such channelling is part of clinical practice and may not be directly applicable to all cancer types or to patients with ongoing or a recent cancer diagnosis, researchers said.

Additional investigation is needed to further examine the association between TNFi treatment for RA and the risk of cancer recurrence.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 13 Aug 2018

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

19 Jul 2018
Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to increase the risk of major bleeding, stroke or systemic embolism, and hospitalization among patients with atrial fibrillation (AF), suggest the results of the RE-LY* trial. Moreover, there is no difference in the safety and efficacy of dabigatran etexilate (DE) 150 and 110 mg twice daily relative to warfarin.
Rachel Soon, 01 Mar 2018

Over half of consumers who use herbal supplements still do not inform physicians of their practices in consultation, according to a local study.